Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Zhengye Biotechnology Holding Limited Ordinary Shares (US:ZYBT), trading at 1.36. In 2025, Zhengye Biotechnology Holding Limited Ordinary Shares generated $116.36 Million in revenue and $703,000 in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Zhengye Biotechnology Holding Limited Ordinary Shares is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: 1.36
- Recent Revenue (2025): $116.36 Million
- Free Cash Flow (2025): $703,000
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.